

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-70) QUAVONLIMAB
 PRONUNCIATION kwa von' li mab
 THERAPEUTIC CLAIM Treatment of advanced solid tumors

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human cytotoxic T-lymphocyte-associated antigen 4) (human-Mus musculus monoclonal M3 γ 1-chain), disulfide with human-Mus musculus monoclonal M3 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G1-kappa, anti-[*Homo sapiens* CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-445) [VH (*Homo sapiens*IGHV3-72*01 (84.7%) -(IGHD) -IGHJ4*01 (92.9%)) CDR-IMGT [8.10.6] (26-33.51-60.99-104) (1-115) -*Homo sapiens*IGHG1*01 (100%) G1m17,1 (CH1 K120 (212) (116-213), hinge 1-15 (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS (444-445)) (116-445)], (224-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens*IGKV1-6*01 (81.6%) -IGKJ2*02 (90.9%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -*Homo sapiens*IGKC*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":227-227")-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa (Source: WHO pINN list 122)

STRUCTURAL FORMULA

Heavy chain

| | | | | | |
|-------------|------------|------------|------------|------------|-----|
| EVQLVESGGG | LVQPGGSLRL | SCAASGFTFS | DNWMNWRQA | PGKGLEWLAQ | 50 |
| IRNKPYNYET | YYSASVKGRF | TISRDDSKNS | VYLMNSLKT | EDTGVYYCTA | 100 |
| QFAYWGQGTL | VTVSSASTKG | PSVFPAPSS | KSTSGGTAAL | GCLVKDYFPE | 150 |
| PVTVSWNSGA | LTSGVHTFPA | VLQSSGLYSL | SSVTVTPSSS | LGTQTYICNV | 200 |
| NHKPSNTKVD | KKVEPKSCDK | THTCPPCPAP | ELLGGPSVFL | FPPKPKDTLM | 250 |
| ISRTPEVTCV | VVDVSHEDPE | VKFNWYVDGV | EVHNAKTKPR | EEQYNSTYRV | 300 |
| VSVLTVLHQD | WLNKKEYKCK | VSNKALPAPI | EKTISKAKGQ | PREPQVYTLF | 350 |
| PSRDELTKNQ | VSLTCLVKGF | YPSDIAVEWE | SNGQPENNYK | TTPPVLDSDG | 400 |
| SFFFLYSKLTV | DKSRWQQGNV | FSCSVMEAL | HNHYTQKSLS | LSPG | 445 |

Light chain

| | | | | | |
|------------|------------|------------|------------|------------|------|
| DIQMTQSPSS | LSASVGDRTV | ITCRTSENIY | GGLNRYQRP | GKSPKLLIYG | 50' |
| ATNLASGVSS | RFGSGSGTD | YTLTISSLQP | EDVATYYCQN | VLRSPFTFGS | 100' |
| GTKLEIKRTV | AAPSDFIFPP | SDEQLKSGTA | SVVCLLNNFY | PREAKVQWKV | 150' |
| DNALQSGNSQ | ESVTEQDSKD | STYSLSSTLT | LSKADYEKHK | VYACEVTHQG | 200' |
| LSSPVTKSFN | RGEC | | | | 214' |

Disulfide bridges

| | | | | | | | |
|----------|-------------|-----------|-------------|-----------|---------------|---------|-------------|
| 2-98 | 22''-98'' | 23'-88' | 23'''-88''' | 134'-194' | 134'''-194''' | 142-198 | 142''-198'' |
| 218-214' | 218''-214'' | 224-224'' | 227-227'' | 259-319 | 259''-319'' | 365-423 | 365''-423 |

Glycosylation sites (N)

295 295''

MOLECULAR FORMULA $C_{6386}H_{9914}N_{1704}O_{2003}S_{42}$

MOLECULAR WEIGHT 143.95 kDa

| | |
|----------------------------|---------------------------|
| TRADEMARK | None as yet |
| SPONSOR | Merck Sharp & Dohme Corp. |
| CODE DESIGNATIONS | MK-1308 |
| <u>CAS</u> REGISTRY NUMBER | 2254059-25-9 |
| UNII | GG0AN49Y59 |
| WHO NUMBER | 11234 |

gbk